Navigation Links
ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
Date:12/31/2008

EXTON, Pa., Dec. 31 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the 27th Annual J.P. Morgan Healthcare Conference at 5:30 P.M. ET (2:30 P.M. PT) on Wednesday, January 14, 2009. The conference is being held at the Westin St. Francis Hotel in San Francisco.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) (vancomycin hydrochloride capsules, USP), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ViroPharma Provides Update on Vancocin(R)
2. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
3. ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
4. ViroPharma to Discuss Commercialization and Launch of Cinryze(TM) on November 5, 2008
5. ViroPharma Incorporated Reports Third Quarter 2008 Financial Results
6. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
7. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
8. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
9. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
10. ViroPharma Provides Update on Vancocin(R)
11. ViroPharma Augments Senior Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... 2017 , ... Occupational pesticide exposure is linked to an ... according to a study released today at the 1st Pan American Parkinson’s and ... pesticides and incidence of sporadic PD through occupational exposure. This latest study, led ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... replacement options at his office, Antoine Dental Center. Currently, patients can get single ... restrictions may apply, but patients can learn more about these offers by contacting ...
(Date:2/24/2017)... , ... February 24, 2017 , ... An in-depth computational ... the University of Pittsburgh points to eight genes that may explain why susceptibility to ... to the results of a study published today in the journal npj Schizophrenia. ...
(Date:2/24/2017)... ... , ... In the Health Care IT campaign, Robert Herjavec discusses health IT ... you will be attacked, but when.” However, he and many others involved highlight a ... Improvements in auditing and monitoring have taken security in health care a very long ...
(Date:2/24/2017)... ... , ... The narrative in “ Signal 8: An Australian Paramedic’s Story ” ... paramedic experiences. Schanssema describes the tragedies he saw, as well as his struggles with ... Schanssema, initially unsure of the career path he wanted to take, found fulfillment in ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Südkorea, 23. Februar 2017 LG Innotek ... Sterilisationsaufgaben vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls ... Strahlung im Bereich zwischen 200 und 280 nm und eignet ... Bakterien, indem es ihre DNA zerstört. Das Produkt von ... ...
(Date:2/23/2017)... Feb. 23, 2017 ITL Limited, ( ASX: ITD ), ... for the half year ended 31 December 2016 compared with the ... presentation can be viewed here . Highlights ... $1.04m; up 104%) Earnings per share of 2.2 ... of $17.5m (Dec 2015: $15.7m; up 11%) Profit ...
(Date:2/23/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies - 2016, provides ... research answers the following questions: What are ... they positioned in the Global Menopause market? What are ...
Breaking Medicine Technology: